Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry's leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly - directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharma's current portfolio includes royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica, Astellas' and Pfizer's Xtandi, Biogen's Tysabri, Johnson & Johnson's Tremfya, Gilead's Trodelvy, Merck's Januvia, Novartis' Promacta, Vertex's Kalydeco, Orkambi, Symdeko and Trikafta, and ten development-stage product candidates.
Unlock the market timeline & signal feed
The order this company entered each market — oldest to newest
Royalty Pharma appoints Kenneth Sun as Asia head
Royalty Pharma appoints Kenneth Sun as Asia head
Sign up to see the full signal feed
How Royalty Pharma's international expansion compares to its competitors
Royalty PharmaYouBars show relative size across the companies compared.
Columns5| Company | Markets | New markets | Momentum | Activity | Expansion score |
|---|---|---|---|---|---|
 Royalty PharmaYou | 0 | 0 | 0% | 0 | 11 |
Not hiring right now
Sign up to track this company and get alerted the moment something changes.
No active campaigns
Sign up to track this company and get alerted the moment something changes.
Royalty Pharma has appointed Kenneth Sun as Senior Vice President and Head of Asia, effective May 2026, to expand its global platform.
Royalty Pharma appoints Kenneth Sun as SVP and Asia head, effective May 2026, to lead royalty business in Asia from Hong Kong.
Royalty Pharma appoints Kenneth Sun as SVP and Asia head, effective May 2026, to lead Asian royalty business from Hong Kong.
Unlock verified emails & direct dials
Free · No credit card needed
Quick answers about Royalty Pharma's business, markets, and growth signals.
Pubrio glocalizes business, people, and intent data from 50+ local sources into one global graph, giving AI and revenue teams full‑market visibility.
© 2026 Pubrio. All rights reserved.
